CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Similar documents

CHEMOTHERAPY JUNE 1986

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile


Fig.1 Chemical structure of BAY o 9867

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

1272 CHEMOTHERAPY MAR. 1975

CHEMOTHERAPY

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

日本化学療法学会雑誌第53巻第S-3号

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote




Fig. 1 Chemical structure of DL-8280


VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers



Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY


CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Key Words: Klebsiella pneumoniae, CEP-AIS, MIC, "MBC", MIC of drugs in combination


Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

VOL.27 S-3 CHEMO THERAPY mido)-3-[[[1- (2-dimethylaminoethyl)-1H-tetrazol-5-yl] -thio] methyl]-ceph-3-em-4-carboxylic acid dihydro- S. aureus 209-P JC

CHEMOTHERAPY MAY. 1988


Fig. 1 Chemical structure of KW-1070

CHEMOTHERAPY



CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str

Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin


CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

Table1MIC of BAY o 9867 against standard strains

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)


VOL. 34 S-2 CHEMOTH8RAPY 913

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1



Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

VOL.42 S-1

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover


CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K


VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

CHEMO THE RAPY OCT. 1994

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

2.7 臨床概要

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis


CHEMOTHERAPY APR. 1982

CHEMOTHERAPY SEPT. 1970

Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis

CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur

Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Table 1. Concentration of ritipenem in plasma, gallbladder tissue and bile after ritipenem acoxil administration (200 mg t.i.d., 3 days) N.D.: not det

(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

日本化学療法学会雑誌第61巻第6号

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.


VOL.39 S-3

VOL. 36 S-3 CHEMOTHERAPY 437

VOL. 43 NO. 4

03-b-„FŒ{›xŒ¾-4.02

02-(a)-Łi’ì™·Łv-4.11

) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky

VOL. 33 S-5 CHEMO THERAPY Fig. 1 Chemical structure of HAPA-B 1-N-[ (2 S)-3-Amino-2-hydroxypropiony1]-4- O-(6-amino-6 - deoxy-ƒ -D- glucopyranosyl) -6


Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

Transcription:

VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp,

CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffkyc, Ps; Peptostreptococcus

VOL. 30 S-3 CHEMOTHERAPY Table 2 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: B; Bacteroides, F; Fusobacterium, E ; Eubacterium, P; Propionibacterium C; Clostridium, *V; Veillonella, **V; Vibrio

CHEMOTHERAPY DEC. 1982 Table 3 Antibacterial activity of T-1982 against anaerobic bacteria Table 4 Antibacterial activity of T-1982 against anaerobic bacteria Note: Sensitivity test media; Brucella blood agar Incubation; 24 hours in an anaerobic cham - ber P; Peptococcus, S; Streptococcus, G; Gaffkya Ps; Peptostreptococcus ; 24 hours in an anaero- (Difco), Incubation bic chamber Note: Sensitivity test media ; Brucella blood agar B ; Bacteroides, F ; Fusobacterium **V ; Vibrio,, *V ; Veillonella, E; Eubacterium, P ; Propionibacterium, C ; Clostridium

VOL.30 S-3 CHEMOTHERAPY Table 5 Antimicrobial activity of T-1982 and other three antimicrobials against Bacteroides fragilis (26 strains) Table 6 Antimicrobial activity of T-1982 and other three antimicrobials against Peptococcus magnus (21 strains) Table 7 Antimicrobial activity of T-1982 and other three antimicrobials against Peptococcus asaccharolyticus (8 strains)

CHEMOTHERAPY DEC. 1982 Table 8 Antimicrobial activity of T-1982 and other three antimicrobials against Peptostreptococcus sp.*(17 strains) *Ps. parvulus, Ps. anaerobius, Ps. micros, S. constellatus, S. intermedius, S. morbillorum, Peptostreptococcus sp. Table 9 Antimicrobial activity of T-1982 and other three antimicrobials against Veillonella parvula (14 strains) Table 10 Antimicrobial activity of T-1982 and other three antimicrobials against Clostridium difficile (20 strains)

CHEMOTHERAPY Fig. 1 Development of resistance of Bacteroides fragilis (GAI-0562) to T-1982, LMOX and CEZ Fig. 3 Ĉ-lactamase activity of Bacteroides fragilis (GAI-0830) 5.30 U/mg of protein Hydrolysis of CEZ=100 Fig. 4 Ĉ-lactamase activity of Bacteroides fragilis (GAI-0548) Fig. 2 Development of resistance of Bacteroides fragilis (GAI-0548) to T-1982, LMOX and CEZ 0.85 U/mg of protein Hydrolysis of CEZ=100

CHEMOTHERAPY DEC. 1982 Fig. 5 j9-lactamase activity fragilis (GAI-0556) of Bacteroides Fig. 8 Morphological changes at various concentration of T-1982, LMOX and CEZ Fig. 6 P-Lactamase activity of Bacteroides fragilis (GAI-0511) Fig. 9 Morphological changes at various concentration of T-1982, LMOX and CEZ Fig. 7 /9-Lactamase activity fragilis (GAI-0763) of Bacteroides

CHEMOTHERAPY Fig.10 Appearance of Clostridium difficile in caecum contents of mice administrated various cephem-antibiotics Table 11 In vivo activity of T-1892 against Bacteroides fragilis (GAI-0558) B. fragilis; 108 CFU/mouse i. p. Grade of recovery of B. fragilis; to Table 12 In vivo activity of T-1982 against Bacteroides fragilis (GAI-0558) Medication: dose; 2 mg/day, route; S. C., term; 7 days *4+: 104 or more/plate, 3+: 104 `103/plate, 2+: 103 `102/plate, 1+: 102 `10 /plate,-: no growth B. fragilis; 108 CFU/mouse i. p. Grade of recovery of B. fragilis; -FFE to

CHEMOTHERAPY

CHEMOTHERAPY ANTIBACTERIAL ACTIVITY OF T-1982 AGAINST ANAEROBES KUNITOMO WATANABE, MIDORIISONO, MAKOTO AOKI TOYOKO KOBAYASHI and KAZUE UENO Institute of Anaerobic Bacteriology, Gifu University, School of Medicine The antibacterial activity of T-1982, a new cephamycin antibiotic, was studied. The following results were obtained. 1) The antibacterial spectrum of T-1982 against anaerobes was almost conformable to that of cefmetazole and cefotetan. Its antibacterial activity against B. fragilis was slightly more potent than that of cefmetazole and cefotetan, with the MIC of 1.56-6.25ƒÊg/ml. Against anaerobic cocci, T-1982 was less active than cefazolin, cefotaxime and cefoperazone but comparable to cefmetazole and cefotetan. The activity was weak against B. thetaiotaomicron, E. lentum, C.difficile and C. rarnosum. 2) Like cefmetazole and cefotetan, T-1982 was very stable to ƒà-laatamase produced by B. fragilis. 3) In the bouillon containing T-1982 (at the MIC), B. fragilis was almost completely lyzed and filamentation was scarcely observed. 4) In the broth containing T-1,982, resistance of B. fragilis was gradually increased with the passage of culture. 5) Following s.c. administration of T-1982 at a dose of 2 mg for 7 days in mice, abnormal growth rate of (C. difficile was 80% in the,cecum, although the number of organisms detected was extremely small. 6) T-1982 exhibited potent in vivo antibacterial activity against B. fragilis intraperitoneally inoculated in mice.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック